文献速递胸部肿瘤

RAS(ON)抑制剂双药联合解除免疫难治性KRASG12C突变NSCLC对免疫检查点阻断的抵抗

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.
PubMed 文献 · Cancer Discov · 2026-01-01

该临床前研究评估RAS(ON) G12C选择性共价抑制剂elironrasib与RAS(ON)多选择性抑制剂daraxonrasib联合,以最大化抑制RAS通路并防止通路再激活。双药诱导深刻且持续的肿瘤消退,克服对失活状态选择性KRASG12C抑制剂的耐药,并在免疫健全模型中增强抗原呈递、重塑抑制性微环境,促进免疫依赖的完全缓解并使免疫难治模型对检查点阻断敏感。

要点

  • RAS(ON)抑制剂双药可深度持续抑制RAS通路并诱导肿瘤消退。
  • 双药克服对失活状态选择性KRASG12C抑制剂的耐药。
  • 双药增强免疫识别并使免疫难治模型对ICB敏感。

核心结论

  • RAS(ON)抑制剂双药联合可克服KRASG12C(OFF)抑制剂耐药机制并增强肿瘤免疫识别,逆转ICB抵抗。

研究设计与样本

  • 临床前研究,在一系列临床前模型中评估elironrasib与daraxonrasib联合。

主要发现

  • RAS(ON)抑制剂双药诱导深刻且持续的肿瘤消退。
  • 双药克服NSCLC中对失活状态选择性KRASG12C抑制剂耐药相关的RAS通路致癌通量增加。
  • 在免疫健全临床前模型中,双药增强抗原呈递并重塑抑制性肿瘤微环境。
  • 双药促进免疫依赖的完全缓解,并使免疫难治模型对检查点阻断敏感。

临床怎么用

  • 为KRASG12C突变NSCLC患者评估RAS(ON)抑制剂双药联合免疫检查点阻断提供临床前依据。

局限性

  • 证据来自临床前模型,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: To address RAS pathway hyperactivation and targeted therapy resistance in KRASG12C-mutant non-small cell lung cancer (NSCLC), we evaluated the potential of the RAS(ON) G12C-selective covalent inhibitor elironrasib and the RAS(ON) multi-selective inhibitor daraxonrasib combination to maximize RAS pathway suppression and forestall pathway reactivation in a series of preclinical models. We demonstrate that the RAS(ON) inhibitor doublet induces profound and sustained tumor regressions and overcomes the increased RAS pathway oncogenic flux that underlies resistance to inactive state-selective KRASG12C inhibitors in NSCLC. Additionally, in immune-competent preclinical models, the RAS(ON) inhibitor doublet enhances tumor immune recognition by boosting antigen presentation and remodeling the suppressive tumor microenvironment, thus promoting immune-dependent complete regressions and sensitization of an immunorefractory model to checkpoint blockade. Collectively, these findings provide a preclinical rationale for the evaluation of a targeted RAS(ON) inhibitor doublet therapy regimen in combination with immune checkpoint blockade (ICB) in patients with KRASG12C-mutant NSCLC. SIGNIFICANCE: The combination of a RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitor mitigates clinical resistance mechanisms to KRASG12C(OFF) inhibitors and enhances tumor immune recognition, overcoming ICB resistance. These preclinical findings highlight the potential for a RAS(ON) targeted therapy regimen in combination with anti-PD-(L)1 in patients with KRASG12C-mutant NSCLC. See related commentary by Molina-Arcas and Downward, p. 1044.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Wei X, Blaj C, Ali Al-Radhawi M, et al. Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade. Cancer Discov. 2026. PMID: 41670434. doi:10.1158/2159-8290.CD-25-1616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。